What is claimed is:

1. Use of a first pharmaceutical therapy and a second pharmaceutical therapy in the manufacture of a medicament for the treatment of a cancer in a patient in need thereof, wherein the first pharmaceutical therapy comprises a nuclease-resistant polynucleotide that hybridizes to a Grb2 nucleic acid in the patient, and wherein the second pharmaceutical therapy comprises a Bcr-Abl tyrosine kinase inhibitor.

2. The use of claim 1, wherein the Bcr-Abl tyrosine kinase inhibitor is dasatinib, imatinib, nilotinib, bosutinib, ponatinib, or bafetinib.

3. The use of claim 1, wherein the Bcr-Abl tyrosine kinase inhibitor is dasatinib.

4. The use of claim 3, wherein the dasatinib is to be administered at a dosage of about 140 mg.

5. The use of claim 3, wherein the dasatinib is to be administered once daily.

6. The use of claim 1, wherein the second pharmaceutical therapy is to be administered systemically.

7. The use of claim 6, wherein the second pharmaceutical therapy is to be administered orally, intraarterially, or intravenously.

8. The use of claim 1, wherein the patient has previously failed treatment with imatinib.

9. Use of a first pharmaceutical therapy and a second pharmaceutical therapy in the manufacture of a medicament for the treatment of a cancer or myelodysplastic syndrome (MDS) in a patient in need thereof, wherein the first pharmaceutical therapy comprises a nuclease-resistant polynucleotide that hybridizes to a Grb2 nucleic acid, and wherein the second pharmaceutical therapy comprises a cytidine analogue.

10. The use of either claim 1 or 9, wherein the polynucleotide hybridizes to the translation initiation site of a Grb2 nucleic acid.

11. The use of any one of claims 1, 9-10, wherein the polynucleotide is an oligonucleotide having a length of 8-50 bases.

12. The use of any one of claims 1, 9-11, wherein the polynucleotide has a sequence according to SEQ ID NO: 1.

13. The use of any one of claims 1, 9-12, wherein the polynucleotide comprises P-ethoxy backbone linkages.

14. The use of any one of claims 1, 9-13, wherein the polynucleotide is encapsulated in a liposome.

15. The use of either claim 1 or 9, wherein the first pharmaceutical therapy further comprises a neutral lipid.

16. The use of either claim 1 or 9, wherein the first pharmaceutical therapy is to be administered systemically.

17. The use of either claim 1 or 9, wherein the first pharmaceutical therapy is formulated for intraarterial or intravenous administration.

18. The use of claim 15, wherein the first pharmaceutical therapy is to be administered at a dosage of from about 60 mg/m^2 and to about 90 mg/m^2.

19. The use of claim 15, wherein the first pharmaceutical therapy is to be administered two to four times per week.

20. The use of claim 9, wherein the cytidine analogue is decitabine, cytarabine, or azacitidine.

21. The use of claim 20, wherein the cytidine analogue is decitabine.

22. The use of claim 20, wherein the cytidine analogue is cytarabine.

23. The use of claim 22, wherein the cytarabine is to be administered at a dosage of about 20 mg.

24. The use of claim 22, wherein the cytarabine is to be administered twice daily.

25. The use of claim 22, wherein the cytarabine is to be administered subcutaneously.

26. The use of either claim 1 or 9, wherein the first pharmaceutical therapy is to be administered prior to the administration of the second pharmaceutical therapy.

27. The use of either claim 1 or 9, wherein the first pharmaceutical therapy and the second pharmaceutical therapy are to be administered concurrently.

28. The use of claim 9, wherein the second pharmaceutical therapy is to be administered prior to the administration of the first pharmaceutical therapy.

29. The use of either claim 1 or 9, wherein the first pharmaceutical therapy and the second pharmaceutical therapy are to be administered by distinct routes.

30. The use of either claim 1 or 9, wherein the patient is a human.

31. The use of either claim 1 or 9, wherein the cancer is colorectal cancer, neuroblastoma, breast cancer, pancreatic cancer, brain cancer, lung cancer, stomach cancer, a blood cancer, skin cancer, testicular cancer, prostate cancer, ovarian cancer, liver cancer or esophageal cancer, cervical cancer, head and neck cancer, non-melanoma skin cancer, or glioblastoma.

32. The use of either claim 1 or 9, wherein the cancer is a blood cancer.

33. The use of claim 32, wherein the blood cancer is a chronic myelogenous leukemia (CML), an acute myeloid leukemia (AML), or a myelodysplastic syndrome (MDS).

34. The use of claim 33, wherein the CML is an accelerated CML or a blast-phase CML.

35. The use of claim 33, wherein the CML or AML is a Bcr-Abl positive CML or Bcr-Abl positive AML.

36. The use of claim 35, wherein the Bcr-Abl positive CML or Bcr-Abl positive AML is positive for a T315I Bcr-Abl mutation.

37. The use of claim 33, wherein the CML or AML is a Philadelphia chromosome-positive CML or Philadelphia chromosome-positive AML.